Once people get used to speed, they can’t go back: The world’s fastest Glycan Profiler, GSL2200

Here is the introduction of GSL2200, which is a world’s fastest glycan profiler adopting the evanescent wave fluorescence excitation method.

Even under the scanning condition that gives the highest sensitivity, the scanning time for one slide is only 10 seconds.
Because the scanning condition that produce the optimal image depends on the sample, scanning is usually performed using several different sets of scanning conditions.
For example, suppose you set the scanning conditions to exposure times of 1, 2, 4, 6, 8, and 10 seconds, even in this case, the total scanning time will be only 31 seconds.
In a case of a conventional laser scanning type scanners, the scanning time varies depending on the resolution setting, but the standard scanning time is around 5 to 10 minutes. If you set several scanning conditions under this type of scammer, the total scanning time can even exceed 30 minutes.
You can see how quickly the GSL2200 can do the job.

You may be concerned about the resolution, but there are absolutely no problems in practical use. The image above shows an example of an image obtained by scanning a LecChip.
The Limit of Detection (LOD) is also sufficiently high as high as 2 ng/mL, providing sufficient performance as a glycan profiler.

Therapeutic potentials targeting Glycan-Glycan Binding Proteins (GPB) interactions

Here is a review paper written by a researcher in Institute of Chemistry, Slovak Academy of Sciences, 845 38 Bratislava, Slovakia about the role of glycans in human.
https://www.mdpi.com/1420-3049/30/13/2678

In this paper, therapeutic potentials targeting glycan-glycan-binding proteins (GBPs), such as selectins, galectins, and Siglecs, are summarized as follows.

    1) Inhibition of GBP–glycan interactions, for example, Uproleselan (Glycomimetics)
    2) Monoclonal antibodies targeting glycans, for example, Dinutuximab/Unituxin (National Cancer Institute) and Naxitamab/Danyelza (Memorial Sloan Kettering Cancer Center) to target ganglioside GD2
    3) Carbohydrate-based vaccines against pathogens and cancer, for example, carbohydrate-based vaccine against the bacteria Haemophilus influenzae type b (Pentacel from Sanofi Pasteur, Hiberix, Merck and Co.), and as vaccines against cancer, Theratope (Biomira), GM2-KLH (Memorial Sloan Kettering Cancer Center), OPT-822 (OBI Pharma), and Racotumomab (Molecular Immunology Center in Havana) targeting sTn antigen, ganglioside GM2, glycolipid Globo H, and ganglioside GM3
    4) Immune checkpoint inhibitor (ICI)
    5) Altering the biosynthesis of carbohydrate determinants with carbohydrate processing inhibitors (CPIs)

Just for your information.

FUT-8 emerges as a potential molecular target for prostate cancer therapy

A group from Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK has reported that FUT-8 could be a a druggable target for prostate cancer therapy.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12086987/

It has been shown that FUT8 as an important driver of prostate cancer progression and points to the need for further characterization of core fucosylation in prostate tumours.
Given the critical roles of FUT8 in prostate cancer biology, it is poised to be a druggable target for cancer therapy.

Identification of bacterial species by applying a machine learning method to LPS glycan profiles obtained by using several lectins

A group from Department of Chemistry, Pavillon Alexandre-Vachon, 1045, avenue de la Médecine, Université Laval, Quebec, Canada has reported Lipopolysaccharide (LPS) detection and its bacteria identification with using a panel of several lectins and by applying a machine learning method on it.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12019741/

The sensing and classification of LPS, which are pivotal constituents of Gram-negative bacteria, are fundamentally important in fields such as healthcare, environmental monitoring, and food safety.

This study presents a new approach utilizing a panel of lectins (from 2 to 7 kinds) immobilized on surface plasmon resonance (SPR) sensors. Each glycan binding profile, which is unique to the bacteria, was used to identify the species of bacteria combining with a machine learning method with high accuracy. Used machine learning methods were Random Forest (RF), k-Nearest Neighbors (kNN), and Support Vector Machine (SVM).

It seems that this kind of detection method using multi-probes combined with a machine learning method is a recent trend in sensing applications.

Are lectins only used in medicine? No, there is good potential in the agricultural field too!

A group from Instituto de Química, Departamento de Química de Biomacromoléculas, Universidad Nacional Autónoma de México has reported about a novel family of lectins, named mytilectins, discovered in bivalve mollusks from view points of glycan binding properties and applications.
https://www.sciencedirect.com/science/article/pii/S0141813025028909?via%3Dihub

Lectins have been evaluated as a probe molecule for tatrgeting tumore cells and also as a therapeutic agant from a medical view point. This paper is proposing to use lectins as a biocontrol agent against phytopathogenic fungi in an agricaltural field.

The antifungal and antioomycete activity of mitilectins against two true fungi and two oomycetes that impact economically in crops are shown in this paper. Mytilectins inhibited fully the growth of the fungi Alternaria alternata and Fusarium oxysporum, as well as the oomycetes Phytophthora capsici and Pythium aphanidermatum. Notably, it is remarkable that mytilectins demonstrated greater inhibition than the commercial antifungal control agent (CAPTAN).

Human Lectin Array

A group from Department of Life Sciences, Imperial College, London SW7 2AZ, United Kingdom has published a paper using human lectin array.
Human Lectin Array

The paper mentioned aboove is the one which was presented about application of a human lectin array at Glyco 26 which was held in Taipei, Aug 27-Sept 1 2023.
39 kinds of human lectins are immobilized on a slide glass.

A conventional existing Lectin array such as LecChip is using mainly plant lectins. I should say that it is GOOD enough in comparative glycan profiling analysis. However, in order to investigate interactions between human body and pathogens, it would be better to use this kind of human lectin arrays rather than conventional lectin arrays.

Environment construction and Python script examples for performing machine learning on glycan structures, cell types, etc. using deep learning using LecChip (lectin microarray) data

In order to use LecChip (lectin microarray) data to identify the structure of glycan structures, cell types, etc., it is effective to use Deep learning on a large amount of data.
The preparations required for this work are as follows.
Python(Anaconda3 is used below)
Tensorflow
Keras
First of all, you need to install these software on your PC and create an environment.

Our product “SA/DL Easy” eliminates such the hassle preparation in advance and allows you to configure Deep learning networks with just a click of a mouse.
Using SA/DL Easy, you can easily enjoy the world for Deep learning without writing scripts like the one below.
When executing the following scripts on your PC, please make sure if the path of the Python script is saved, the path of the saved input data, the path of the folder where the learning results and test results are correctly specified.
———————————————————————————————
# An example of Deep learning Python Script for identifing glycan structures, cell types, etc. using LecChip data.

from __future__ import print_function
import numpy as np
import csv
import pandas
from keras.datasets import mnist
from keras.models import Sequential
from keras.layers.core import Dense, Dropout, Activation
from keras.optimizers import RMSprop
from keras.utils import np_utils
from make_tensorboard import make_tensorboard

np.random.seed(1671) # for reproducibility

# network and training
NB_EPOCH = 100 # how many times you want to let them learn.
BATCH_SIZE = 2  # divide the dataset into several subsets
VERBOSE = 1
NB_CLASSES = 2 # final output number
OPTIMIZER = RMSprop() # optimizer
N_HIDDEN = 45  # number of nodes in the hidden layer is set to 45 here according to the number of lectins used in LecChip.
VALIDATION_SPLIT = 0.2 # percentage of the training data used as test data
DROPOUT = 0.3
LECTINS = 45

def drop(df):
return df[pandas.to_numeric(df.iloc[:, 2], errors=’coerce’).notnull()]

# data is normalized so that the maximum value is 1.
def normalize_column(d):
dmax = np.max(d)
dmin = np.min(d)
return (np.log10(d + 1.0) – np.log10(dmin + 1.0)) / \
(np.log10(dmax + 1.0) – np.log10(dmin + 1.0))

def normalize(data):
return np.apply_along_axis(normalize_column, 0, data)

# The input data should be in CSV file format
df1 = drop(pandas.read_csv(r’c:\Users\Masao\Anaconda3\DL_scripts\cell.csv’)).reset_index(drop=True)
X_train = normalize(df1.iloc[:, 2:].astype(np.float64))
family_column = df1.iloc[:, 1]
family_list = sorted(list(set(family_column)))
Y_train = np.array([family_list.index(f) for f in family_column])

df2 = drop(pandas.read_csv(r’c:\Users\Masao\Anaconda3\DL_scripts\cell_test.csv’)).reset_index(drop=True)
X_test = normalize(df2.iloc[:, 2:].astype(np.float64))
familyt_column = df2.iloc[:, 1]
familyt_list = sorted(list(set(familyt_column)))
Y_test = np.array([familyt_list.index(f) for f in familyt_column])

print(X_train.shape[0], ‘train samples’)
print(X_test.shape[0], ‘test samples’)

# convert class vectors to binary class matrices
Y_train = np_utils.to_categorical(Y_train, NB_CLASSES)
Y_test = np_utils.to_categorical(Y_test, NB_CLASSES)

print(X_train)
print(Y_train)
print(X_test)
print(Y_test)

# An example of neural network configuration
# 2 hidden layers
# Input is LecChip data (using 45 lectins)
# The final layer is activated with softmax

model = Sequential()
model.add(Dense(N_HIDDEN, input_shape=(LECTINS,)))
model.add(Activation(‘relu’))
model.add(Dropout(DROPOUT))
model.add(Dense(N_HIDDEN))
model.add(Activation(‘relu’))
model.add(Dropout(DROPOUT))
model.add(Dense(NB_CLASSES))
model.add(Activation(‘softmax’))
model.summary()

# to visualize the learning and the test results with Tensorboard
callbacks = [make_tensorboard(set_dir_name=’Glycan_Profile’)]

model.compile(loss=’categorical_crossentropy’,
optimizer=OPTIMIZER,
metrics=[‘accuracy’])

model.fit(X_train, Y_train,
batch_size=BATCH_SIZE, epochs=NB_EPOCH,
callbacks=callbacks,
verbose=VERBOSE, validation_split=VALIDATION_SPLIT)

score = model.evaluate(X_test, Y_test, verbose=VERBOSE)
print(“\nTest score:”, score[0])
print(‘Test accuracy:’, score[1])

————————————————————————————
# Python Script for using Tensorboard

# -*- coding: utf-8 -*-
from __future__ import absolute_import
from __future__ import unicode_literals
from time import gmtime, strftime
from keras.callbacks import TensorBoard
import os

def make_tensorboard(set_dir_name=”):
ymdt = strftime(“%a_%d_%b_%Y_%H_%M_%S”, gmtime())
directory_name = ymdt
log_dir = set_dir_name + ‘_’ + directory_name
os.mkdir(log_dir)
tensorboard = TensorBoard(log_dir=log_dir, write_graph=True, )
return tensorboard

————————————————————————————
To visualize the learning and test results,
run $ make_tensorboard.py,
run $ tensorboard –logdir=./Glycan_Profile_Mon_10_Feb_2025_23_06_26 (./folder where data is recorded),
and access http://localhost:6006/ with your browser.

(base) PS C:\Users\masao\Anaconda3\DL_Scripts> python make_tensorboard.py
Using TensorFlow backend.
(base) PS C:\Users\masao\Anaconda3\DL_Scripts> tensorboard –logdir=./Glycan_Profile_Mon_10_Feb_2025_23_06_26
Serving TensorBoard on localhost; to expose to the network, use a proxy or pass –bind_all
TensorBoard 2.0.2 at http://localhost:6006/ (Press CTRL+C to quit)

—————————————————————————————————-
LecChip data is in CSV format as shown below.
From the left, the sample name, family name (this will be the training data), and numerical values ​​of various lectins are listed.

—————————————————————————————————-
After the training, you should save the model.
If the model was saved, it could be restored, and unknown data can be given to make predictions.
Those scripts will be uploaded separately for your information.

Vision for the Evolution of AI

Sam Altman of OpenAI gave a talk at the University of Tokyo on the “Vision for the Evolution of AI”.

The following is a quote from what was said in the talk:
When a student asked, “How do you think society will change in the next 10, 30, or 100 years?”, Altman replied, “In 10 years, AI will accelerate advances in science and technology, in 30 years, all aspects of society will be integrated with AI and will evolve together, and as for what the future will look like 100 years from now, it’s hard to imagine at this point, but human life will be completely different than it is now.”

It is certain that advances in AI will have positive impacts on human life. However, this will remain true as long as AI will be just a human tool. This is very similar to the situation where someone asks someone else to do something that they think is troublesome or time-consuming for him/her. It’s just like that the other person here has been replaced by AI. By having someone do the troublesome and time-consuming tasks for you, you can focus on more productive works. As AI’s inference capabilities improve further, unseen solutions that humans have never thought of may be discovered, and thereby science and technology will advance at an accelerated speed.

The problem is 100 years from now. If AI’s abilities exceed those of humans, we will probably lose the will to fight intelligently, just as ordinary people would when they encountered a genius they couldn’t compete with. There is a strong possibility that this feeling of inferiority, that you cannot win even if you think about it, will deprive you of motivation, and that humans will simply become animals that are used by AI.
In that era, people were liberated from production activities, and intellectual activities, which were once a source of income, became worthless in the face of an AI that could neither fight nor win, and became nothing more than just an existence for fun?

The only way to overcome this problem that we will encounter at this point is for humans to evolve in the same way as AI and acquire abilities that are equal to or better than AI. It will be an era where AI and the human brain will merge. At that time, if this creature can be called a human? I’m not even sure that.

A new lectin ALA might be effective on CCA treatments

A group from Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Thailand has reported about a new lectin ALA extracted from the seeds of Artocarpus lakoocha.
https://www.nature.com/articles/s41598-024-84444-7

ALA exhibits agglutinin activity and has binding specificity to T- and Tn-associated glycoproteins and monosaccharides such as Gal and GalNAc.

It was confirmed that glycans identified by ALA were elevated in human Cholangiocarcinoma (CCA) tissues.
ALA significantly reduced cell viability of CCA cells, KKU-100 and KKU-213B, in a dose-dependent manner (up to 30 µg/mL) with approximately a 30% decrease observed at the highest concentration. And also, ALA significantly reduced the migration and invasion ability of KKU-100 and KKU-213B cells in a dose-dependent manner with 1–2 µg/mL which did not affect cell viability.

These results suggest their therapeutic potential effects on CCA treatments.

A new glycobiomarker for discriminating Psoriatic Arthritis (PsA) and Rheumatoid Arthritis (RA)

A group from Division of Laboratory Diagnostics, Department of Laboratory Diagnostics, Faculty of Pharmacy, Wroclaw Medical University, Poland has reprted about a new glycobiomarker, change in glycosylation pattern of serum clusterin, for discriminating Psoriatic Arthritis (PsA) and Rheumatoid Arthritis (RA).
https://www.mdpi.com/1422-0067/25/23/13060

PsA and RA are connective tissue autoimmune diseases.
The present study aimed to check whether serum clusterin (CLU) concentration and its glycosylation pattern may be markers differentiating these diseases.

The followings were found.
Clusterin concentrations were significantly lower in the sera of the RA patients compared to the PsA group, and there were no other significant differences between the examined groups in CLU concentration.

The relative reactivities of CLU glycans with SNA (α2-6 Sia binding lectin) were significantly higher in the RA and PsA patients in comparison to the control group. There were no significant differences between the studied groups in the relative reactivities of CLU glycans with MAA (α2-3 Sia binding lectin).

These results indicate that PsA and RA can be distinguished by CLU concentration and sialic acid modification (by SNA).

Powered by WordPress |Copyright © 2020 Emukk. All rights reserved